profit from every $100 of sales.
$0$100
Cencora
$359.03+2.76% today
-1.8% in 1 year
1-year low $252.741-year high $374.75
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $44.08 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cencora sold, what it kept, and what it did with the cash.
Sales went from $239 billion in 2022 to $321 billion in 2025, with $1.55 billion of profit last year.
SalesProfit
Cencora handed back 27% of the cash it generated last year.
Buybacks $435M$437M
Free cash flow 2025$3.2B
Bought back its own shares$435M
Paid as dividends$437M
Cash vs. debt$4.4B vs. $7.7B
Cencora vs. similar companies
Cencora grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cencora | 44.1× · Expensive | ||
 McKesson | 26.7× · Fair price | ||
 Cardinal Health | 41.6× · Expensive | ||
 Sigma Healthcare | 63.0× · Very expensive | ||
 Henry Schein | 23.9× · Fair price |
Compare Cencora with Cardinal Health · Eli Lilly · McKesson
AI analysis
An AI analyst reads Cencora's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 189,894 | 213,989 | 238,587 | 262,173 | 293,959 | 321,333 | |
| 5,192 | 6,943 | 8,296 | 8,959 | 9,910 | 11,479 | |
| – | – | 2,754 | 2,686 | 3,157 | 3,934 | |
| -4,744 | 2,859 | 3,104 | 3,371 | 3,371 | 3,747 | |
| -3,409 | 1,540 | 1,699 | 1,745 | 1,509 | 1,554 | |
| -16.65 | 7.39 | 8.04 | 8.53 | 7.53 | 7.96 | |
| 2.7% | 3.2% | 3.5% | 3.4% | 3.4% | 3.6% | |
| – | – | 1.2% | 1.0% | 1.1% | 1.2% | |
| -1.8% | 0.7% | 0.7% | 0.7% | 0.5% | 0.5% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 44,275 | 57,338 | 56,561 | 62,559 | 67,102 | 76,590 |
| Cash | 4,598 | 2,547 | 3,388 | 2,592 | 3,133 | 4,356 |
| Total debt | 4,120 | 6,684 | 5,703 | 4,787 | 4,388 | 7,661 |
| Total liabilities | – | – | 56,489 | 61,892 | 66,315 | 74,843 |
| -1,019 | 223 | -212 | 522 | 646 | 1,508 | |
| 205 | 208 | 211 | 205 | 200 | 195 | |
| -130.8% | 26.9% | 34.4% | 35.6% | 35.4% | 23.1% | |
| 334.5% | 689.5% | -803.0% | 334.3% | 233.6% | 103.1% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 2,207 | 2,667 | 2,703 | 3,911 | 3,485 | 3,875 | |
| 370 | 438 | 496 | 458 | 487 | 668 | |
| 1,837 | 2,228 | 2,207 | 3,453 | 2,998 | 3,207 | |
| Dividends paid | 344 | 367 | 392 | 399 | 416 | 437 |
| 420 | 82 | 484 | 1,181 | 1,491 | 435 | |
| 74 | 100 | 93 | 125 | 148 | 148 |
Valuation
- 44.1×
- 20.4×
- –
- 44.8×
- 0.2×
- 21.4×
- 19.2×
- 4.7%
- 2.3%
- 0.9%
Profitability
- 3.6%
- 1.2%
- 0.5%
- 1.2%
- 23.7%
- 32.9%
- 115.9%
- 3.1%
- 16.5%
- –
Growth
- +11.1%
- –
- +7.0%
- +5.8%
- −2.6%
Financial health
- 0.9×
- 5.08
- 15.2%
- 6.4×
- 0.90
- 0.59
- 4.03
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 5%of 946
Bottom 30%of 871
Bottom 29%of 563
Bottom 49%of 867
Top 22%of 986
What analysts expect
- Average price target
- $409.14
- Range
- $360.00 – $440.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 4.75 | 4.82 | −1.5% |
| Feb 4, 2026 | 4.08 | 4.05 | +0.7% |
| Nov 5, 2025 | 3.84 | 3.79 | +1.3% |
| Aug 6, 2025 | 4.00 | 3.85 | +3.9% |
| May 7, 2025 | 4.42 | 4.11 | +7.5% |
| Feb 5, 2025 | 3.73 | 3.50 | +6.6% |
| Nov 6, 2024 | 3.34 | 3.23 | +3.4% |
| Jul 31, 2024 | 3.34 | 3.22 | +3.7% |
0.9%of the share price, paid each year
On $1,000 invested$9a year at today's yield, before tax
+5.8%2020 to 2025
Raised5 yearsin a row, in our data
Paid per share, each year
$3.00 in 2015 → $2.25 in 2025
How safe it looks
28.1% of its profit
Room to growStretchedMore than it earns: 13.6%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
57No pass
Benjamin Graham
22No pass
Philip Fisher
45No pass
Peter Lynch
29No pass
Joel Greenblatt
29No pass
Charlie Munger
54No pass
Terry Smith
62Pass
Questions about Cencora
Is Cencora a good stock to buy?
A business with weak numbers, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cencora AI analysis
What does Cencora do?
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. It is in Medical Distribution, based in Conshohocken, PA, United States, with 47,000 employees.
Does Cencora pay a dividend?
Yes. At today's price the dividend is 0.9% a year, about 28% of its yearly profit. In 2025 it paid out $437 million in dividends.
Is Cencora stock halal?
Yes. Cencora passes our halal screen: its business is permitted and its debt is 11% of its market value, under the 30% limit. How we check
How has Cencora stock done over the past year?
Down 1.8% over the past twelve months, to $359.03. It traded between $252.74 and $374.75 and is 4.2% below its high.
Who are Cencora's competitors?
The largest listed companies in the same industry are McKesson, Cardinal Health, Sigma Healthcare and Henry Schein. The peers table on this page compares their profit, growth and price with Cencora's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.